Contents
- The general rules concerning the value sets established in…
- Translation of the coded elements into the national langua…
- For all data fields not mentioned in the following value s…
- If for any reason the preferred code systems listed below…
- Member States using other coding in their systems shall ma…
- As some value sets based on the coding systems provided fo…1 change
- 1. Disease or agent targeted/Disease or agent from which the holder has recovered: COVID-19 (SARS-CoV-2 or one of its variants)
- 2. COVID-19 vaccine or prophylaxis
- 3. COVID-19 vaccine medicinal product5 changes
- 4. COVID-19 vaccine marketing authorisation holder or manufacturer1 change
- 5. Number in a series of doses as well as the overall number of doses in the series1 change
- 6. Member State or third country in which the vaccine was administered/test was carried out
- 7. The type of test1 change
- 8. Manufacturer and commercial name of the test used (optional for NAAT test)1 change
- 9. Result of the test
5.2. Booster doses
—2/1 indicates the administration of a booster dose following a primary single-dose vaccination course, or the administration of a booster dose following the completion of a primary course consisting of one dose of a 2-dose vaccine administered to a recovered person in line with the vaccination protocol applied by a Member State. After that, doses (X) administered following the first booster dose shall be indicated by (2+X)/(1) > 1 (3/1, for example),
—3/3 indicates the administration of a booster dose following a primary 2-dose vaccination series. After that, doses (X) administered following the first booster dose shall be indicated by (3+X)/(3+X) = 1 (4/4, for example).
Where the person is receiving doses following the primary vaccination series, such booster doses shall be reflected in the corresponding certificates as follows:
Member States shall implement the encoding rules set out in this Section by 1 February 2022.
Member States shall, automatically or upon request by the persons concerned, re-issue certificates in which the administration of a booster dose following a primary single-dose vaccination course is encoded in such a way that it cannot be distinguished from the completion of the primary vaccination series.
For the purposes of this Annex, references to ‘booster doses’ should be understood as also covering additional doses administered to better protect individuals who mount inadequate immune responses following the completion of the standard primary vaccination series. Within the legal framework established by Regulation (EU) 2021/953, Member States may take measures to address the situation of vulnerable groups who may receive additional doses as a matter of priority. For example, if a Member State decides to administer additional doses only to specific sub-groups of the population, it can choose, in accordance with Article 5(1) of Regulation (EU) 2021/953, to issue vaccination certificates indicating the administration of such additional doses only upon request and not automatically. Where such measures are taken, Member States shall inform the persons concerned accordingly, as well as that they may continue to make use of the certificate received following the completion of the standard primary vaccination series.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.